

## **Methodological Note for Disclosures of Transfer of Value For Reporting Year 2024**

---

### **Introduction**

This note describes the methodology used by Leadiant Biosciences Ltd (“Leadiant”) to identify, collate and report transfers of value disclosures, in compliance with the Association of British Pharmaceutical Industry (ABPI) code. The ABPI code requires disclosures of all transfers of value to healthcare organisations (HCOs), healthcare professionals (HPs) and other relevant decision makers (ORDMs) in the year previous to year of disclosure. This note will report on transfers of value made in the period January 1<sup>st</sup> 2024 and December 31<sup>st</sup> 2024.

Information about disclosable payments made by Leadiant to members of the public or to Patient Organisations is disclosed on Leadiant’s company website, as required and if paid.

### **Definitions**

#### **Healthcare Organisation (HCO):**

Refers to either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or an organisation through which one or more health professionals or other relevant decision makers provide services. If a healthcare organisation consists of only one health professional or other relevant decision maker, then it would be subject to the requirements in the

Code regarding individual health professionals.

**Health Professional (HP):**

Includes any member of the medical, dental, pharmacy or nursing profession and any other person who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine. The term also includes any employee of a pharmaceutical company whose primary occupation is that of a practising health professional.

**Other relevant decision makers (ORDM):**

Includes someone with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who is not a health professional.

**Transfer of Value (ToV):**

Means a direct or indirect transfer of value, whether in cash, in-kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. A direct transfer of value is one made directly by a company for the benefit of a recipient. An indirect transfer of value is one made on behalf of a company for the benefit of a recipient or through an intermediate and where the company knows or can identify the recipient that will benefit from the transfer of value.

*Research and Development (R&D):*

HCO/HP transfers of value that relate to the planning and conduct of: Non-clinical studies (as defined in OECD Principles on Good Laboratory Practice), Clinical trials (as defined in Directive 2001/20/EC), Non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HPs specifically for the study. This also includes investigator sponsored research (ISRs). Non-interventional

studies that are retrospective in nature are included within aggregate disclosure for R&D in this reporting year.

In case of differences between the EFPIA reporting definitions and the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for categorisation of transfers of value, the methodology used reflects the ABPI definitions.

*Donations:*

Benefits in kind provided to HCOs for specified use.

*Grants:*

Funding provided to HCOs/HPs in response to a request to support a specific activity that provides educational benefit or enhances patient care. This includes unsolicited requests for funds and/or product for investigator-initiated research or projects for patient benefit.

*Congress and educational event sponsorship:*

Expenses related to the sponsorship of HCOs as congress organisers in exchange for corporate benefits at an event (e.g., booth space, hosting of a symposium, stands, advertising on programs or banners and room hire or catering if paid on behalf of an HCO).

*Fees:*

Transfers of Value which are fees paid for service resulting from or related to contracts between companies and institutions, organisations, HPs or associations of HPs under which such institutions, organisations or associations provide any type of services to the company or any other type of funding not covered in the previous categories.

## **Identification of Transfers of Value**

To identify all transfers of value, all payments for Grants, Sponsorship, Donations and Consultancy fees made in 2024 by Leadiant Biosciences UK were screened, and those fitting the requirements of transfers of value were included. These were cross-checked against the compliance approval system in the company for the period between 1st of January 2024 and 31st December 2024. Indirect transfers of value were also identified and included.

## **Data Privacy**

Leadiant Biosciences discloses the data on the basis of legitimate interests. Consent to disclose is included in the grant/sponsorship agreements but consent is not specifically confirmed prior to publication.

## **Beneficiary**

Where a transfer of value is made to a health professional indirectly via a healthcare organisation, where possible Leadiant aims to disclose the transfers of value made to the health professional that the payment benefits, as per the ABPI code. Leadiant discloses the exact amount paid to the HP, HCO or ORDM. This may include VAT, if VAT was included on the invoice. For transfers of value where a product is provided free of cost for research, the amount disclosed is calculated using the unit list price in the country concerned.

## **Currency**

All transfers of value specified in our disclosure are denominated in pounds sterling. If the original payment was made in Euros, we have converted the

amount into GBP using the foreign exchange rate on closing on the day of payment. Amounts disclosed in GBP may therefore vary from the exact amount paid in the local currency.

## **Location**

All transfers of value are disclosed on the Disclosure UK portal, irrespective of where the recipient of the transfer of value resides. Transfers of Value Disclosure is made even if the payments, etc. are made by Leadiant's overseas affiliates.

## **Multi-Year Contracts**

Where a contract for any Transfer of Value runs for more than one year and thus disclosure cycles, Leadiant will disclose Transfers of Value relating to that contract in the year the Transfer of Value was made (which may be different to the year in which the contract was agreed or signed).